Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: A systematic review

Oncologist

Volumn 18, Issue 1, 2013, Pages 54-63

  Hung, Anna ^a   Danielmullins, C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Aged; Colorectal neoplasms; Comparative effectiveness research; Drug therapy; Treatment outcome

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL EFFECTIVENESS; CODING; COLON CANCER; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 84873028702     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0050     Document Type: Article

References (59)

1. Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med 2009; 151: 203-205.
2. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. PLoS Med. 2009; 6: e1000097.
3. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med 1997; 127: 37.
4. Cook DJ, Greengold NL, Ellrodt AG et al. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997; 127: 210-216.
5. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998; 317: 465-468.
6. Petticrew M. Why certain systematic reviews reach uncertain conclusions. BMJ 2003; 326: 756-758.
7. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press, 2009.
8. Holden DJ, Jonas DE, Porterfield DS et al. Systematic review: Enhancing the use and quality of colorectal cancer screening. Ann Intern Med 2010; 152: 668-676.
9. Jellema P, van der Windt DA, Bruinvels DJ et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: Systematic review and meta-analysis. BMJ 2010; 340: 1269.
10. Patel S, McCall M, Ohinmaa A et al. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg 2011; 253: 666-671.
11. Pickhardt PJ, Hassan C, Halligan S et al. Colorectal cancer: CTcolonographyandcolonoscopy for detection: Systematic review and meta-analysis. Radiology 2011; 259: 393-405.
12. van der Pas MH, Meijer S, Hoekstra OS et al. Sentinel-lymph-node procedure in colon and rectal cancer: Asystematic reviewandmeta-analysis. Lancet Oncol 2011; 12: 540-550.
13. Des Guetz G, Schischmanoff O, Nicolas P et al. Doesmicrosatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? Asystematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-1896.
14. Ho TW, Mack LA, Temple WJ. Operative salvage for retroperitoneal nodal recurrence in colorectal cancer: A systematic review. Ann Surg Oncol 2011; 18: 697-703.
15. Cantero-Munoz P, Urien MA, Ruano-Ravina A. Efficacy and safety of intraoperative radiotherapy in colorectal cancer: A systematic review. Cancer Lett 2011; 306: 121-133.
16. Chua TC, Saxena A, Liauw W et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17: 492-501.
17. Wieser M, Sauerland S, Arnold D et al. Perioperative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer 2010; 10: 309.
18. Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA 2011; 305: 2335-2342.
19. Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC et al. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anticancer Drugs 2010; 21: 749-758.
20. Galfrascoli E, Piva S, Cinquini M et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. Dig Liver Dis 2011; 43: 286-294.
21. Welch S, Spithoff K, Rumble RB et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: A systematic review. Ann Oncol 2010; 21: 1152-1162.
22. Jensen SA, Lonborg JT, Sorensen JB. Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences. Acta Oncol 2006; 45: 67-76.
23. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
24. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev 2005; 31: 380-402.
25. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer. Available at http: //www. nccn. org/professionals/ physician_gls/f_guidelines. asp. Accessed October 19, 2012.
26. Zuckerman IH, Rapp T, Onukwugha E et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 2009; 57: 1403-1410.
27. McKibbin T, Frei CR, Greene RE et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. The Oncologist 2008; 13: 876-885.
28. Haller D, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471.
29. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1, 864 patients. J Clin Oncol 2007; 25: 102-109.
30. Raman AK. Bevacizumab (BV) related adverse eventsamongvariousagegroupsof elderly patients with advanced colorectal cancer. J Clin Oncol 2007; 25: 145-146.
31. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. NEngl JMed 2001; 345: 1091-1097.
32. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
33. Chau I, Norman AR, Cunningham D et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91: 1453-1458.
34. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABPC-08: Arandomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385-3390.
35. Moehler M, Ababneh Y, Verpoort K et al. Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: An observational study. Onkologie 2010; 33: 684-690.
36. Howlander N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
37. Au HJ, Mulder KE, Fields AL. Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 2003; 3: 165-171.
38. Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. The Oncologist 2008; 13: 390-402.
39. Power D, Lichtman S. Chemotherapyfor the elderly patient with colorectal cancer. Cancer 2010; 16: 241-252.
40. Muss HB, Biganzoli L, Sargent DJ et al. Adjuvant therapy in the elderly: Making the right decision. J Clin Oncol 2007; 25: 1870-1875.
41. Schrag D, Cramer LD, Bach PB et al. Ageandadjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857.
42. Lemmens VE, van Halteren AH, Janssen-Heijnen MLet al. Adjuvant treatment for elderly patients with stage IIIcoloncancerinthesouthern Netherlandsis affected by socioeconomic status, gender, and comorbidity. Ann Oncol 2005; 16: 767-772.
43. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
44. Chagpar R, Xing Y, Chiang Y et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 2012; 30: 972-979.
45. Abraham A, Habermann E, Rothenberger D et al. Adjuvantchemotherapyfor stage III colon cancer in the oldest old: Results beyond clinical guidelines. Cancer 2012 [Epub ahead of print].
46. Seymour MT, Thompson LC, Wasan HS et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. Lancet 2011; 377: 1749-1759.
47. Bensmaine MA, Marty M, de Gramont A et al. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/-folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 2001; 85: 509-517.
48. Mattioli R, Massacesi C, Recchia F et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16: 1147-1151.
49. Rosati G, Cordio S, Bordonaro R et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomized phase II study. Ann Oncol 2010; 21: 781-786.
50. Pfeiffer P, Sorbye H, Ehrsson H et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 2006; 17: 252-258.
51. Sakamoto J, Ohashi Y, Hamada C et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year resultsfromthreerandomizedtrials. J Clin Oncol 2004; 22: 484-492.
52. Mattioli R, Lippe P, Recchia F et al. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 2001; 21: 489-492.
53. Fata F, Mirza A, Craig G et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: A 10-year experience of the Geisinger Medical Center. Cancer 2002; 94: 1931-1938.
54. Chau I, Norman AR, Cunningham D et al. Arandomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557.
55. Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 2006; 92: 290-294.
56. Andre T, Boni C, Mounedji-Boudiaf L et al. Multicenter international study of oxaliplatin/5-fluorouracil/ leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
57. Lee D. Highlights from 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, LA, June 2004. Clin Colorectal Cancer 2004; 4: 154-158.
58. Diaz Rubio E. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). J Clin Oncol 2004; 22: 3737.
59. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 2003; 361: 457-464.